Valued at USD 762.26 million in 2025, the peptide synthesis market is projected to reach USD 819.62 million in 2026 and USD 1,482.67 million by 2034, growing at a CAGR of 7.7% during the forecast period 2026–2034. Key players include Bachem Holding AG, Biotage, Creative Diagnostics, GenScript, Lonza, Merck KGaA, PolyPeptide Group, Puresynth Research Chemicals Pvt Ltd., Syngene International Limited, and Thermo Fisher Scientific Inc. This analysis examines diagnostics, outsourced manufacturing, artificial intelligence, and regulation across the value chain.

Peptide-Based Diagnostics and Molecular Imaging

The expanding use of peptides in diagnostics and imaging supports peptide synthesis market development by improving disease detection and monitoring. Peptides are widely used in biomarker identification, targeted contrast agents, and molecular imaging because of their high binding affinity and specificity, and radiolabeled peptides have improved the accuracy and efficiency of diagnostic assays, immunoassays, and imaging techniques. Advances in peptide-based diagnostics, including probe development, allow more precise imaging of tumors, neurological disorders, and infectious diseases.

Strategic investment is following. In June 2024, Lantheus acquired global rights to Life Molecular’s RM2 technology for USD 35 million, covering radiotherapeutic and diagnostic compounds targeting GRPR receptors in cancer cells, with clinical trials planned for 2025.

Precision Medicine Expands the Need for Synthetic Peptides

The rise of precision medicine and immunotherapies is creating opportunities for suppliers. The need for highly specific and custom synthetic peptides continues to rise with advanced research in rare diseases and precision medicine, and the FDA reported in November 2024 that over 30 million Americans suffer from over 7,000 rare diseases. Rising investment in genomics and proteomics research also improves drug discovery by directing the identification of novel therapeutic targets, while government initiatives, private funding, and research collaborations strengthen infrastructure for synthetic peptides.

The increasing adoption of personalized medicine has accelerated demand for peptide-based treatments that offer precise and tailored options for individual patients. The effect is visible in cell therapy development, where peptide-based solutions are enabling breakthrough treatments; in August 2024, TG Therapeutics, a partner of Precision BioSciences, received FDA IND clearance for azer-cel, an allogeneic CAR T therapy, to begin Phase 1 trials for progressive multiple sclerosis.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/peptide-synthesis-market

Outsourced Manufacturing and End-User Demand

By end user, Polaris covers pharmaceutical and biotechnology companies, contract development and manufacturing organization and contract research organization providers, and academic and research institutes. The contract development and manufacturing organization model is illustrated by SynCrest Inc., a peptide and nucleotide CRDMO that expanded its services globally in May 2023, offering continuous flow synthesis with in-line measurement for APIs, intermediates, and raw materials.

Global companies compete through innovation, strategic partnerships, and geographic expansion, offering solid-phase and liquid-phase synthesis as well as automated platforms, while regional players focus on cost-effective solutions and localized services in emerging markets. Competitive strategies include mergers and acquisitions, collaborations with biopharmaceutical companies, and the development of novel synthesis methods to improve efficiency and scalability.

Artificial Intelligence and Regulatory Requirements

Artificial intelligence is influencing production. AI helps generate peptides rapidly through data analysis and optimization, predicts peptide structure alongside formulation improvement, reduces trial and error in drug creation, and helps manufacturers optimize processes to reduce wastage and cost.

Regulation remains a defining factor. The FDA in the US and EMA in Europe require strict adherence to standards for quality, manufacturing uniformity, purity, stability, and safety. Because peptides are highly unstable, special care is needed in synthesis, purification, and storage, and Good Manufacturing Practice, validation, and quality control are necessary for approval. Extensive preclinical and clinical studies must also demonstrate efficacy, dose safety, and possible side effects before commercialization.

Future Outlook

Polaris describes the outlook as promising, driven by peptide therapeutics in oncology, metabolic diseases, infections, and precision medicine applications. Anticipated increases in biotech spending, growing requirements for biologics, and innovations in automated synthesis are expected to fuel growth, while Peptide Synthesis  engineering, AI, and large-scale production will shape next-generation drugs.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market